HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $73

HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.

HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.

Total
0
Shares
Related Posts